Keyword: Boehringer Ingelheim
Two dual EGFR/HER2 inhibitors from Boehringer Ingelheim and Puma showed in vitro activity against AML cancer cells.
Chris Corsico left the CMO spot at Boehringer Ingelheim to fill a new role at GlaxoSmithKline: senior vice president of development.
The takeover is focused on VSV candidates Boehringer sees becoming key components of its efforts to gain ground in the immuno-oncology sector.
Different KRAS mutations exert diverging effects on protein function, a new study illustrates.
Boehringer will work with British academics and Oxford BioMedica to develop an inhaled, lentiviral vector-based gene therapy for cystic fibrosis.
NBE will use the money to start testing anti-ROR1 antibody-drug conjugate NBE-002 in solid tumor patients.
Boehringer Ingelheim has unveiled a €230 million ($268 million) investment in its biologics capacity.
Gilead is committing to milestones that could exceed $400 million to snag exclusive rights to two technologies in the indications.
U.S.-China biotech Xynomic Pharma has raised additional funding to take an HDAC inhibitor in-licensed last year into seven new cancer trials.
Boehringer gained the global rights to OSE's SIRP-alpha antagonist, which is in development for solid tumors.